Kalvista Pharm Stock Price, News & Analysis
Company Description
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) is a global pharmaceutical company focused on developing and delivering oral therapies for individuals affected by rare diseases with significant unmet needs. According to company disclosures and recent press releases, KalVista has concentrated its efforts on hereditary angioedema (HAE), a rare genetic disease characterized by painful and potentially life‑threatening swelling attacks linked to dysfunction of the C1 esterase inhibitor protein and uncontrolled activation of the kallikrein‑kinin system.
KalVista’s lead commercial product is EKTERLY (sebetralstat), described by the company as a novel plasma kallikrein inhibitor. EKTERLY is approved in multiple major markets, including the United States, European Union, United Kingdom, Switzerland, Australia, Singapore and Japan, for the treatment of acute attacks of HAE in people 12 years of age and older. Company materials consistently state that EKTERLY is the first and only oral on‑demand treatment for HAE, offering treatment of attacks without injections.
Business focus and therapeutic area
Public filings and press releases describe KalVista as being dedicated to oral therapies for rare diseases, with a particular emphasis on HAE. The company applies its knowledge of the kallikrein‑kinin system and oral drug discovery to develop small‑molecule protease inhibitor medicines for diseases driven by plasma kallikrein and Factor XIIa. This scientific focus underpins the discovery and development of sebetralstat and related programs.
KalVista reports that its team discovered and developed EKTERLY and continues to work closely with the global HAE community to improve treatment and care. The company highlights the role of early treatment of HAE attacks, consistent with treatment guidelines that recommend treating attacks as soon as possible to prevent progression and shorten attack duration.
EKTERLY (sebetralstat) and global approvals
Company communications indicate that EKTERLY received U.S. Food and Drug Administration (FDA) approval as a novel plasma kallikrein inhibitor for the treatment of acute HAE attacks in adults and pediatric patients aged 12 years and older. Subsequent regulatory approvals have been obtained in the European Union, United Kingdom, Switzerland, Australia, Singapore and Japan for similar indications in individuals aged 12 and older.
KalVista reports that EKTERLY has been launched commercially in the United States and Germany, with additional launches planned or progressing through partners in other regions. In Japan, EKTERLY will be commercialized by Kaken Pharmaceutical Co., Ltd. In Latin America, KalVista has granted Multicare Pharmaceuticals, LLC exclusive rights to commercialize sebetralstat in Brazil, Argentina, Colombia and Mexico, with Multicare responsible for regulatory approval and distribution. Licensing agreements with Pendopharm in Canada and Kaken in Japan further extend EKTERLY’s commercial reach.
Clinical development and HAE studies
KalVista’s regulatory approvals for EKTERLY are supported by data from the phase 3 KONFIDENT clinical trial, described as the largest clinical study ever conducted in HAE, with 136 patients randomized across 66 clinical sites in 20 countries. Results published in the New England Journal of Medicine showed that EKTERLY achieved significantly faster symptom relief, reduction in attack severity, and attack resolution than placebo, with a safety profile similar to placebo.
The company also references the KONFIDENT‑S open‑label extension trial, in which patients treated HAE attacks with sebetralstat in real‑world‑like conditions. Reported data include rapid time to dosing after attack onset, early symptom relief, and high levels of patient satisfaction among participants who switched from injectable on‑demand treatments. In European participants, interim KONFIDENT‑S analyses presented at scientific meetings showed median times to treatment measured in minutes and median times to beginning of symptom relief measured in hours.
For pediatric patients aged 2 to 11 years, KalVista is conducting the KONFIDENT‑KID trial, an open‑label study of sebetralstat using a proprietary oral disintegrating tablet (ODT) formulation and weight‑based dosing. Interim results presented at medical congresses indicate early treatment of attacks, median times to dosing and symptom relief, and a tolerability profile without serious or treatment‑related adverse events in the reported dataset. The company has stated that enrollment in KONFIDENT‑KID was completed ahead of schedule and that it expects to file a U.S. regulatory application for this pediatric population.
Commercialization and partnerships
KalVista’s disclosures describe a growing commercial footprint for EKTERLY. The company initiated its U.S. commercial launch in July 2025 and has reported increasing net product revenue, patient start forms, and activated prescribers. In subsequent updates, KalVista has highlighted that prescription refills have become a major driver of EKTERLY revenue in the U.S., which the company interprets as evidence of ongoing utilization and patient satisfaction.
Internationally, KalVista has launched EKTERLY in Germany and notes strong early adoption, with prescribing behaviors that the company views as consistent with trends observed in the U.S. The company has also entered into strategic licensing and commercialization agreements with regional partners, including Kaken Pharmaceutical in Japan, Pendopharm in Canada, and Multicare Pharmaceuticals in Latin America, to manage local regulatory processes and distribution.
Corporate structure and capital markets
According to SEC filings, KalVista Pharmaceuticals, Inc. is incorporated in Delaware and its common stock trades on The Nasdaq Stock Market under the ticker symbol KALV. The company has used capital markets instruments such as convertible senior notes to fund operations, including commercialization of EKTERLY and general corporate purposes. For example, an 8‑K filing describes the issuance of 3.250% Convertible Senior Notes due 2031, with terms governing interest, maturity, conversion features, and events of default.
KalVista’s public filings also document matters of corporate governance, including annual meetings of stockholders, election of directors, committee composition, inducement equity awards for new executives, and compensation arrangements. These filings provide insight into the company’s governance practices, board structure, and use of stock‑based incentives to attract and retain personnel.
Research, publications, and scientific engagement
KalVista regularly presents data related to EKTERLY and HAE at international scientific and medical meetings. Presentations at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting and the German Allergy Congress have covered topics such as patient satisfaction with sebetralstat, barriers to timely on‑demand treatment with injectable therapies, pediatric interim results from KONFIDENT‑KID, and European experience with sebetralstat in KONFIDENT and KONFIDENT‑S.
These presentations, along with peer‑reviewed publications, form part of the company’s strategy to share clinical evidence with clinicians, researchers, and the HAE community. Survey data presented by external experts and supported by KalVista highlight issues such as delays in treatment due to injection aversion, logistical challenges, and patient preference for oral on‑demand options.
Hereditary angioedema and unmet need
Company materials describe hereditary angioedema as a rare genetic disease involving deficiency or dysfunction of C1 esterase inhibitor and subsequent uncontrolled activation of the kallikrein‑kinin system. People with HAE can experience recurrent attacks of tissue swelling in various parts of the body, which may be painful, debilitating, and potentially life‑threatening depending on the site of swelling.
KalVista emphasizes that treatment guidelines recommend early treatment of all attacks, regardless of location or severity, to prevent progression and shorten time to resolution. The company positions EKTERLY as an oral on‑demand option that may reduce barriers associated with injectable therapies, such as injection‑site reactions, administration burden, and lack of privacy, based on survey findings presented at scientific meetings.
Company status
Recent SEC filings and press releases show that KalVista remains an active, publicly traded company on The Nasdaq Stock Market under the symbol KALV. The filings include periodic financial results, corporate governance updates, and disclosures related to financing transactions and executive appointments. There is no indication in the provided materials of delisting, deregistration, completed merger, or bankruptcy.